FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211112106> ?p ?o ?g. }

• W4211112106 abstract "Background Seborrhoeic dermatitis is a chronic inflammatory skin condition that is distributed worldwide. It commonly affects the scalp, face and flexures of the body. Treatment options include antifungal drugs, steroids, calcineurin inhibitors, keratolytic agents and phototherapy. Objectives To assess the effects of antifungal agents for seborrhoeic dermatitis of the face and scalp in adolescents and adults. A secondary objective is to assess whether the same interventions are effective in the management of seborrhoeic dermatitis in patients with HIV/AIDS. Search methods We searched the following databases up to December 2014: the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 11), MEDLINE (from 1946), EMBASE (from 1974) and Latin American Caribbean Health Sciences Literature (LILACS) (from 1982). We also searched trials registries and checked the bibliographies of published studies for further trials. Selection criteria Randomised controlled trials of topical antifungals used for treatment of seborrhoeic dermatitis in adolescents and adults, with primary outcome measures of complete clearance of symptoms and improved quality of life. Data collection and analysis Review author pairs independently assessed eligibility for inclusion, extracted study data and assessed risk of bias of included studies. We performed fixed‐effect meta‐analysis for studies with low statistical heterogeneity and used a random‐effects model when heterogeneity was high. Main results We included 51 studies with 9052 participants. Of these, 45 trials assessed treatment outcomes at five weeks or less after commencement of treatment, and six trials assessed outcomes over a longer time frame. We believe that 24 trials had some form of conflict of interest, such as funding by pharmaceutical companies. Among the included studies were 12 ketoconazole trials (N = 3253), 11 ciclopirox trials (N = 3029), two lithium trials (N = 141), two bifonazole trials (N = 136) and one clotrimazole trial (N = 126) that compared the effectiveness of these treatments versus placebo or vehicle. Nine ketoconazole trials (N = 632) and one miconazole trial (N = 47) compared these treatments versus steroids. Fourteen studies (N = 1541) compared one antifungal versus another or compared different doses or schedules of administration of the same agent versus one another. Ketoconazole Topical ketoconazole 2% treatment showed a 31% lower risk of failed clearance of rashes compared with placebo (risk ratio (RR) 0.69, 95% confidence interval (CI) 0.59 to 0.81, eight studies, low‐quality evidence) at four weeks of follow‐up, but the effect on side effects was uncertain because evidence was of very low quality (RR 0.97, 95% CI 0.58 to 1.64, six studies); heterogeneity between studies was substantial (I² = 74%). The median proportion of those who did not have clearance in the placebo groups was 69%. Ketoconazole treatment resulted in a remission rate similar to that of steroids (RR 1.17, 95% CI 0.95 to 1.44, six studies, low‐quality evidence), but occurrence of side effects was 44% lower in the ketoconazole group than in the steroid group (RR 0.56, 95% CI 0.32 to 0.96, eight studies, moderate‐quality evidence). Ketoconozale yielded a similar remission failure rate as ciclopirox (RR 1.09, 95% CI 0.95 to 1.26, three studies, low‐quality evidence). Most comparisons between ketoconazole and other antifungals were based on single studies that showed comparability of treatment effects. Ciclopirox Ciclopirox 1% led to a lower failed remission rate than placebo at four weeks of follow‐up (RR 0.79, 95% CI 0.67 to 0.94, eight studies, moderate‐quality evidence) with similar rates of side effects (RR 0.9, 95% CI 0.72 to 1.11, four studies, moderate‐quality evidence). Other antifungals Clotrimazole and miconazole efficacies were comparable with those of steroids on short‐term assessment in single studies. Treatment effects on individual symptoms were less clear and were inconsistent, possibly because of difficulties encountered in measuring these symptoms. Evidence was insufficient to conclude that dose or mode of delivery influenced treatment outcome. Only one study reported on treatment compliance. No study assessed quality of life. One study assessed the maximum rash‐free period but provided insufficient data for analysis. One small study in patients with HIV compared the effect of lithium versus placebo on seborrhoeic dermatitis of the face, but treatment outcomes were similar. Authors' conclusions Ketoconazole and ciclopirox are more effective than placebo, but limited evidence suggests that either of these agents is more effective than any other agent within the same class. Very few studies have assessed symptom clearance for longer periods than four weeks. Ketoconazole produced findings similar to those of steroids, but side effects were fewer. Treatment effect on overall quality of life remains unknown. Better outcome measures, studies of better quality and better reporting are all needed to improve the evidence base for antifungals for seborrhoeic dermatitis." @default.
• W4211112106 created "2022-02-13" @default.
• W4211112106 creator A5021601955 @default.
• W4211112106 creator A5028757956 @default.
• W4211112106 creator A5044874947 @default.
• W4211112106 creator A5060017728 @default.
• W4211112106 creator A5079266214 @default.
• W4211112106 date "2015-04-28" @default.
• W4211112106 modified "2023-10-16" @default.
• W4211112106 title "Topical antifungals for seborrhoeic dermatitis" @default.
• W4211112106 cites W1272285534 @default.
• W4211112106 cites W1493578925 @default.
• W4211112106 cites W1829967433 @default.
• W4211112106 cites W1900540719 @default.
• W4211112106 cites W1903437055 @default.
• W4211112106 cites W1921127631 @default.
• W4211112106 cites W1927566350 @default.
• W4211112106 cites W195695305 @default.
• W4211112106 cites W1964379525 @default.
• W4211112106 cites W1964696318 @default.
• W4211112106 cites W1965723189 @default.
• W4211112106 cites W1966425517 @default.
• W4211112106 cites W1975222467 @default.
• W4211112106 cites W1980363333 @default.
• W4211112106 cites W1985434572 @default.
• W4211112106 cites W1987798574 @default.
• W4211112106 cites W1992718780 @default.
• W4211112106 cites W1998560367 @default.
• W4211112106 cites W1999541518 @default.
• W4211112106 cites W2000680272 @default.
• W4211112106 cites W2001610193 @default.
• W4211112106 cites W2003668609 @default.
• W4211112106 cites W2004545095 @default.
• W4211112106 cites W2006545967 @default.
• W4211112106 cites W2007393113 @default.
• W4211112106 cites W2008678022 @default.
• W4211112106 cites W2010212789 @default.
• W4211112106 cites W2010696390 @default.
• W4211112106 cites W2010715928 @default.
• W4211112106 cites W2012713776 @default.
• W4211112106 cites W2016867427 @default.
• W4211112106 cites W2022247920 @default.
• W4211112106 cites W2024071876 @default.
• W4211112106 cites W2028938970 @default.
• W4211112106 cites W2034465018 @default.
• W4211112106 cites W2037140709 @default.
• W4211112106 cites W2045689534 @default.
• W4211112106 cites W2049228926 @default.
• W4211112106 cites W2059331477 @default.
• W4211112106 cites W2059471668 @default.
• W4211112106 cites W2060990534 @default.
• W4211112106 cites W2062621353 @default.
• W4211112106 cites W2064469690 @default.
• W4211112106 cites W2069316711 @default.
• W4211112106 cites W2070624913 @default.
• W4211112106 cites W2072618703 @default.
• W4211112106 cites W2073112584 @default.
• W4211112106 cites W2075093963 @default.
• W4211112106 cites W2078277689 @default.
• W4211112106 cites W2078530486 @default.
• W4211112106 cites W2080299731 @default.
• W4211112106 cites W2086569466 @default.
• W4211112106 cites W2090434317 @default.
• W4211112106 cites W2092616197 @default.
• W4211112106 cites W2094392170 @default.
• W4211112106 cites W2100054195 @default.
• W4211112106 cites W2100172241 @default.
• W4211112106 cites W2108140211 @default.
• W4211112106 cites W2109677515 @default.
• W4211112106 cites W2112675673 @default.
• W4211112106 cites W2126969449 @default.
• W4211112106 cites W2130730925 @default.
• W4211112106 cites W2131243653 @default.
• W4211112106 cites W2135514072 @default.
• W4211112106 cites W2138855302 @default.
• W4211112106 cites W2141309750 @default.
• W4211112106 cites W2143703269 @default.
• W4211112106 cites W2144149632 @default.
• W4211112106 cites W2168618229 @default.
• W4211112106 cites W2188080234 @default.
• W4211112106 cites W2326059208 @default.
• W4211112106 cites W2465777630 @default.
• W4211112106 cites W3183766821 @default.
• W4211112106 cites W39920583 @default.
• W4211112106 cites W4240427040 @default.
• W4211112106 cites W4255157952 @default.
• W4211112106 cites W944992043 @default.
• W4211112106 cites W2121047870 @default.
• W4211112106 doi "https://doi.org/10.1002/14651858.cd008138.pub2" @default.
• W4211112106 hasPublicationYear "2015" @default.
• W4211112106 type Work @default.
• W4211112106 citedByCount "8" @default.
• W4211112106 countsByYear W42111121062017 @default.
• W4211112106 countsByYear W42111121062018 @default.
• W4211112106 countsByYear W42111121062019 @default.
• W4211112106 countsByYear W42111121062020 @default.
• W4211112106 countsByYear W42111121062021 @default.
• W4211112106 countsByYear W42111121062022 @default.
• W4211112106 crossrefType "reference-entry" @default.
• W4211112106 hasAuthorship W4211112106A5021601955 @default.

• next